Connecting Korean Innovation with Boston’s Global Startup & Investment Ecosystem
Join leading investors, founders, biotech experts, and innovators from Korea and Boston for an evening of cross-border collaboration, startup networking, and global innovation exchange. Hosted as part of Venture Café Cambridge Thursday Gathering, this special program is designed to connect promising Korean deep tech and biotech startups with Boston’s world-class startup, investment, and research ecosystem.
The event will feature VC-led panel discussions on biotech exits, cross-border investment strategies, founder experiences, AI innovation showcases, startup networking, and interactive Skillthon presentations. Participants will have opportunities to engage directly with venture capitalists, entrepreneurs, biotech leaders, and innovation ecosystem experts from both Korea and the Greater Boston area.
Co-organized by: Consulate General of the Republic of Korea in Boston, Korea Health Industry Development Institute (KHIDI), Korea Technology and Information Promotion Agency for SMEs (TIPA), Korea Evaluation Institute of Industrial Technology (KEIT), and Seoul National University Hospital.
Featured Korean Startups & Companies
Portrai: Portrai is an AI-powered spatial biology company developing next-generation drug discovery platforms through spatial transcriptomics and advanced data analytics. The company integrates AI with spatial biology to uncover new therapeutic insights and accelerate precision medicine innovation.
(portrai.io)
Space LiinTech: Space LiinTech is a pioneering space biopharma company building microgravity-based drug research platforms for in-orbit pharmaceutical R&D. By combining biotechnology and space infrastructure, the company is expanding new frontiers for drug discovery and space medicine innovation.
(spaceliintech.com)
PROTEINA: PROTEINA is a leading biotech company specializing in single-molecule protein interaction analysis for precision therapeutics and AI-driven drug discovery. Its proprietary SPID platform enables ultra-high-resolution protein-protein interaction analysis to support next-generation antibody and biomarker development. (proteina.co.kr)
Txinno Bioscience: Txinno Bioscience is a biotech company developing small molecule and TPD to treat cancers. Txinno’s flagship pipeline, TXN10128 (ENPP1 inhibitor, Ph1), has demonstrated clinical PoC as the combo partner for chemo/ADC as the essential immune remodeler that improves DoR. Txinno has also advanced its preclinical pipeline, TXN12923, the first ULK1 PROTAC that suppresses autophagy-mediated
resistance to RAS-targeted treatments. (eng.txinno.com)
MedimabBio: MedimabBio is a biotech startup developing innovative antibody-based therapeutics and precision medicine solutions targeting unmet medical needs. The company focuses on advancing novel biologics and translational research to improve patient outcomes in complex diseases. (medimabbio.com)
Elisigen: Elisigen is a biotechnology company developing next-generation gene and cell therapy platforms for precision healthcare innovation. The company is focused on translating cutting-edge biomedical research into scalable therapeutic solutions for global healthcare markets. (elisigen.com)
Join us at Venture Café for an engaging panel discussion that unpacks the realities of doing business in Saudi Arabia. Hear from experienced practitioners as they challenge common assumptions, share insights on the entrepreneurial landscape, and discuss emerging opportunities for founders, investors, and partners.
Whether you’re curious about the market or actively exploring the region, this is a chance to learn, ask questions, and connect. This event is hosted by the Babson Global Center for Entrepreneurial Leadership (BGCEL) whose purpose is to promote the entrepreneurial ecosystem of Saudi Arabia, and is part of a bootcamp for Saudi founders to scale their businesses hosted at Babson College.